肝素市场规模、份额和成长分析（按产品类型、给药途径、成分、供应、治疗方法领域、规格、类型、包装和地区划分）－2026-2033年产业预测

预计到 2024 年，全球肝素市场规模将达到 75.1 亿美元，到 2025 年将达到 77.1 亿美元，到 2033 年将达到 94.6 亿美元，预测期（2026-2033 年）的复合年增长率为 2.6%。

全球肝素市场是医疗保健和製药业的重要组成部分，主要集中在动物性抗凝血剂领域。心血管疾病病例增加、人口老化以及外科手术数量上升导致抗凝血剂需求不断增长，这是推动市场成长的主要因素。此外，与文明病相关的健康问题和住院率上升也促进了对肝素产品的需求。持续进行研发工作，开发先进的肝素递送系统，也对市场成长产生了正面影响。然而，监管审查力度加大、市场竞争加剧以及肝素诱发的血小板减少性疾病併发症潜在併发症等挑战可能会阻碍市场成长。儘管存在这些障碍，但生物相似药、创新药物递送系统以及新兴市场的成长等机会，仍为市场带来了可观的前景。

全球肝素市场驱动因素

全球肝素市场主要受心血管疾病高发生率的推动，心血管疾病是全球死亡和残疾的主要原因。心肌梗塞、心房颤动和中风等疾病会显着增加血栓性栓塞症的风险，增加对肝素及类似抗凝血剂的需求。此外，肺动脉栓塞（PE）和深层静脉栓塞症（DVT）的发病率上升也推动了对肝素的需求，因为肝素已成为治疗这些疾病的标准治疗方法。这些健康挑战共同确保了对有效抗凝血疗法的持续需求，从而支撑了市场成长。

限制全球肝素市场的因素

全球肝素市场面临许多限制因素，其中最主要的是肝素治疗可能带来的副作用，尤其是出血风险，这会导致病人焦虑和医护人员谨慎用药。此外，诸如肝素诱发的血小板减少性疾病（HIT）等疾病也会带来严重风险，并可能削弱人们对治疗通讯协定的信心。而且，使用未分级肝素需要密切监测活化部份凝血活酵素时间（aPTT），这会使治疗方案更加复杂，并需要更精细的管理流程，尤其是在门诊环境中。这些因素共同构成了肝素市场的挑战。

全球肝素市场趋势

目前，全球肝素市场正经历生物相似药研发和应用的强劲成长趋势。随着原厂肝素製剂专利的到期，经济高效的生物相似药的出现为医疗机构提供了一种在不影响患者照护品质的前提下有效控製成本的可行方案。这种转变在欧洲和北美等关键地区尤其明显，相关人员越来越重视药品采购中的可负担性。对生物相似药日益增长的关注反映了市场环境的变化，其特征是治疗方案的竞争加剧和创新，同时也凸显了市场向更永续、更公平的医疗保健解决方案转变的趋势。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管环境
• 案例研究
• 技术进步

全球肝素市场规模（按产品类型和复合年增长率划分）（2026-2033 年）

• 未分级肝素
• 低分子量肝素（LMWH）
• 超低分子量肝素（ULMWH）

全球肝素市场规模（依给药途径划分）及复合年增长率（2026-2033 年）

• 口服
• 肠外给药

全球肝素市场规模（按来源和复合年增长率划分）（2026-2033 年）

• 牛衍生
• 源自猪

全球肝素市场规模（依成分及复合年增长率划分）（2026-2033 年）

• 钠
• 钙
• 其他的

全球肝素市场规模（按供应类型和复合年增长率划分）（2026-2033 年）

• 原料
• 加工产品

全球肝素市场规模（依治疗领域划分）及复合年增长率（2026-2033 年）

• 深层静脉栓塞症
• 肺动脉栓塞
• 血栓性栓塞症
• 其他的

全球肝素市场规模（依治疗领域划分）及复合年增长率（2026-2033 年）

• 循环系统
• 呼吸系统
• 肿瘤学
• 肾臟病学
• 中枢神经系统（CNS）
• 其他的

全球肝素市场规模（按规格和复合年增长率划分）（2026-2033 年）

• 10 至 1000 个单位
• 1000至5000个单位
• 5,000 至 25,000 台
• 其他的

全球肝素市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 学名药
• 品牌产品

全球肝素市场规模（按容器类型和复合年增长率划分）（2026-2033 年）

• 瓶子
• 包包
• 管瓶
• 其他的

全球肝素市场规模（按包装类型和复合年增长率划分）（2026-2033 年）

• 玻璃
• 塑胶

全球肝素市场规模（依分销管道划分）及复合年增长率（2026-2033 年）

• 医院药房
• 零售药局和药局
• 网路药房
• 其他的

全球肝素市场规模（依应用领域划分）及复合年增长率（2026-2033 年）

• 术前准备
• 术后护理
• 肾臟透析
• 诊断测试
• 其他的

全球肝素市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 诊所
• 居家医疗
• 门诊手术中心
• 其他的

全球肝素市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Opocrin SpA（Italy）
• Baxter International Inc.（US）
• Pfizer Inc.（US）
• Bioiberica SAU（Spain）
• Fresenius SE & Co. KGaA（Germany）
• Hebei Changshan Biochemical Pharmaceutical Co., Ltd.（China）
• B. Braun SE（Germany）
• Dr. Reddy's Laboratories Ltd.（India）
• LEO Pharma A/S（Denmark）
• Aspen Holdings（South Africa）
• Gland Pharma（India）
• Hikma Pharmaceuticals（United Kingdom）
• Techdow USA（US）
• Viatris Inc.（US）
• Biological E. Limited（India）
• Shenzhen Hepalink Pharmaceutical Group Co., Ltd.（China）
• Faran Shimi Pharmaceutical Company（Iran）
• Octapharma AG（Switzerland）
• Kamada Ltd.（Israel）

结论与建议

Global Heparin Market size was valued at USD 7.51 Billion in 2024 and is poised to grow from USD 7.71 Billion in 2025 to USD 9.46 Billion by 2033, growing at a CAGR of 2.6% during the forecast period (2026-2033).

The global heparin market is a crucial segment within the healthcare and pharmaceutical industries, focusing on anticoagulant medications derived from animal tissues. It is primarily fueled by rising cardiovascular disease cases, an increasing aging population, and a higher volume of surgical procedures, leading to greater demand for anticoagulants. Additionally, lifestyle-related health issues heighten the need for heparin products, supported by increasing hospitalization rates. Ongoing research and development efforts aimed at creating advanced heparin delivery systems also contribute positively to market growth. However, challenges such as regulatory scrutiny, intense market competition, and potential complications like heparin-induced thrombocytopenia may hinder growth. Despite these obstacles, the market shows promise through opportunities in biosimilars, innovative drug delivery systems, and growth in emerging markets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Heparin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Heparin Market Segments Analysis

Global Heparin Market is segmented by Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User and region. Based on Product Type, the market is segmented into Unfractionated Heparin, Low Molecular Weight Heparin (LMWH) and Ultra-Low Molecular Weight Heparin (ULMWH). Based on Mode of Administration, the market is segmented into Oral Administration and Parenteral Administration. Based on Source, the market is segmented into Bovine and Porcine. Based on Ingredient, the market is segmented into Sodium, Calcium and Others. Based on Availability, the market is segmented into Raw and Processed. Based on Treatment, the market is segmented into Deep Vein Thrombosis, Pulmonary Embolism, Arterial Thromboembolism and Others. Based on Therapeutics, the market is segmented into Cardiovascular, Respiratory, Oncology, Nephrology, CNS and Others. Based on Strength, the market is segmented into 10 -1000 Unit, 1000 -5000 Unit, 5000- 25000 Unit and Others. Based on Type, the market is segmented into Generics and Brands. Based on Container, the market is segmented into Bottles, Bags, Vials and Others. Based on Packaging, the market is segmented into Glass and Plastic. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Drug Store, Online Pharmacy and Others. Based on Application, the market is segmented into Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Diagnostic Tests and Others. Based on End User, the market is segmented into Hospitals, Clinics, Homecare, Ambulatory Surgical Centres and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Heparin Market

The global Heparin market is significantly driven by the prevalence of cardiovascular diseases, which are the primary causes of mortality and disability worldwide. Conditions such as heart attacks, atrial fibrillation, and strokes greatly elevate the risk of thromboembolic disorders, thereby amplifying the need for heparin and similar anticoagulants. Additionally, the increasing incidence of pulmonary embolism (PE) and deep vein thrombosis (DVT) further fuels the demand for heparin, as it is considered the standard of care for managing these conditions. This combination of health challenges ensures a sustained requirement for effective anticoagulant therapies, supporting market growth.

Restraints in the Global Heparin Market

The global heparin market faces significant restraints due to the potential side effects associated with heparin therapy, particularly the risk of bleeding, which can lead to apprehension among patients and caution among healthcare providers. Additionally, conditions such as heparin-induced thrombocytopenia (HIT) pose serious risks that can undermine confidence in treatment protocols. Furthermore, the requirement for meticulous monitoring of activated partial thromboplastin time (aPTT) when using unfractionated heparin complicates the treatment regimen, particularly in outpatient settings, leading to more complex management routines. These factors collectively contribute to the challenges faced by the heparin market.

Market Trends of the Global Heparin Market

The Global Heparin market is currently witnessing a strong trend towards the development and adoption of biosimilars. As patents for original heparin formulations expire, the emergence of cost-effective biosimilars presents a viable alternative, enabling healthcare providers to manage costs while ensuring patient care remains uncompromised. This shift is particularly pronounced in major regions such as Europe and North America, where stakeholders are increasingly prioritizing affordability in drug procurement. The growing emphasis on these biosimilars underscores a broader market shift towards more sustainable and equitable healthcare solutions, reflecting an evolving landscape defined by enhanced competition and innovation in therapeutic options.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Heparin Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Unfractionated Heparin
• Low Molecular Weight Heparin (LMWH)
• Ultra-Low Molecular Weight Heparin (ULMWH)

Global Heparin Market Size by Mode of Administration & CAGR (2026-2033)

• Market Overview
• Oral Administration
• Parenteral Administration

Global Heparin Market Size by Source & CAGR (2026-2033)

• Market Overview
• Bovine
• Porcine

Global Heparin Market Size by Ingredient & CAGR (2026-2033)

• Market Overview
• Sodium
• Calcium
• Others

Global Heparin Market Size by Availability & CAGR (2026-2033)

• Market Overview
• Raw
• Processed

Global Heparin Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Deep Vein Thrombosis
• Pulmonary Embolism
• Arterial Thromboembolism
• Others

Global Heparin Market Size by Therapeutics & CAGR (2026-2033)

• Market Overview
• Cardiovascular
• Respiratory
• Oncology
• Nephrology
• CNS
• Others

Global Heparin Market Size by Strength & CAGR (2026-2033)

• Market Overview
• 10 -1000 Unit
• 1000 -5000 Unit
• 5000- 25000 Unit
• Others

Global Heparin Market Size by Type & CAGR (2026-2033)

• Market Overview
• Generics
• Brands

Global Heparin Market Size by Container & CAGR (2026-2033)

• Market Overview
• Bottles
• Bags
• Vials
• Others

Global Heparin Market Size by Packaging & CAGR (2026-2033)

• Market Overview
• Glass
• Plastic

Global Heparin Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy and Drug Store
• Online Pharmacy
• Others

Global Heparin Market Size by Application & CAGR (2026-2033)

• Market Overview
• Pre-Surgical Procedures
• Post-Surgical Procedures
• Kidney Dialysis
• Diagnostic Tests
• Others

Global Heparin Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Homecare
• Ambulatory Surgical Centres
• Others

Global Heparin Market Size & CAGR (2026-2033)

• North America (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
  • US
  • Canada
• Europe (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Opocrin S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioiberica S.A.U. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LEO Pharma A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aspen Holdings (South Africa)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gland Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Techdow USA (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biological E. Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Faran Shimi Pharmaceutical Company (Iran)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kamada Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations